Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States; Institute for Molecular Life Sciences, University of Zürich, Zürich, Switzerland
Luciane P Capelo
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States; Instituto de Ciência e Tecnologia, Universidade Federal de São Paulo, São Paulo, Brazil
Claudio Cantù
Institute for Molecular Life Sciences, University of Zürich, Zürich, Switzerland; Wallenberg Centre for Molecular Medicine, Department of Clinical and Experimental Medicine (IKE), Faculty of Health Sciences, Linköping University, Linköping, Sweden
Dario Zimmerli
Institute for Molecular Life Sciences, University of Zürich, Zürich, Switzerland
Nehal Gosalia
Regeneron Pharmaceuticals, Tarrytown, United States
Steven Pregizer
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
Karen Cox
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
Satoshi Ohte
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States; Department of Microbial Chemistry, Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan
Marina Feigenson
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
Laura Gamer
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, United States
Jeffry S Nyman
Department of Orthopaedic Surgery and Rehabilitation, Vanderbilt University Medical Center, Nashville, United States
Two decades after signals controlling bone length were discovered, the endogenous ligands determining bone width remain unknown. We show that postnatal establishment of normal bone width in mice, as mediated by bone-forming activity of the periosteum, requires BMP signaling at the innermost layer of the periosteal niche. This developmental signaling center becomes quiescent during adult life. Its reactivation however, is necessary for periosteal growth, enhanced bone strength, and accelerated fracture repair in response to bone-anabolic therapies used in clinical orthopedic settings. Although many BMPs are expressed in bone, periosteal BMP signaling and bone formation require only Bmp2 in the Prx1-Cre lineage. Mechanistically, BMP2 functions downstream of Lrp5/6 pathway to activate a conserved regulatory element upstream of Sp7 via recruitment of Smad1 and Grhl3. Consistent with our findings, human variants of BMP2 and GRHL3 are associated with increased risk of fractures.